Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae336 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Dahlene Fusco und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Tulane Medical Center, New Orleans, Louisiana, USA. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Alanine, Antiviral Agents, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Gilead Sciences, Inc..
Abstract (Originalsprache)
Background
Remdesivir, an RNA-polymerase prodrug inhibitor approved for treatment of coronavirus disease 2019 (COVID-19), shortens recovery time and improves clinical outcomes. This prespecified analysis compared remdesivir plus standard of care (SOC) with SOC alone in adults hospitalized with COVID-19 requiring oxygen support in the early stage of the pandemic.
Methods
Data for 10-day remdesivir treatment plus SOC from the extension phase of an open-label study (NCT04292899) were compared with real-world, retrospective data on SOC alone (EUPAS34303). Both studies included patients aged ≥18 years hospitalized with severe acute respiratory syndrome coronavirus 2 up to 30 May 2020, with oxygen saturation ≤94% on room air or supplemental oxygen (all forms), and with pulmonary infiltrates. Propensity score weighting was used to balance patient demographics and clinical characteristics across treatment groups. The primary endpoint was time to all-cause mortality or end of study (day 28). Time to discharge, with a 10-day landmark to account for duration of remdesivir treatment, was a secondary endpoint.
Results
A total of 1974 patients treated with remdesivir plus SOC, and 1426 with SOC alone, were included after weighting. Remdesivir significantly reduced mortality versus SOC (hazard ratio [HR], 0.46; 95% confidence interval, .39–.54). This association was observed at each oxygen support level, with the lowest HR for patients on low-flow oxygen. Remdesivir significantly increased the likelihood of discharge at day 28 versus SOC in the 10-day landmark analysis (HR, 1.64; 95% confidence interval: 1.43–1.87).
Conclusions
Remdesivir plus early-2020 SOC was associated with a 54% lower mortality risk and shorter hospital stays compared with SOC alone in patients hospitalized with COVID-19 requiring oxygen support. Clinical Trials Registration. ClinicalTrials.gov NCT04292899 and EUPAS34303.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Tulane Medical Center, New Orleans, Louisiana, USA.
- Real World Evidence, Gilead Sciences, Inc., Foster City, California, USA.
- Department of Biostatistics, University of California, Berkeley, Berkeley, California, USA.
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
- Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
- Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Ivana Malenica, Huldrych F Günthard, Anand P Chokkalingam
Förderung
- Gilead Sciences, Inc.
Zitieren
APA
Fusco, D., Malenica, I., Günthard, H. F., Gupta, S. K., Kurbegov, D., Balani, B., Olender, S., Aberg, J. A., Telep, L. E., Tian, Y., Blair, C., Wu, G., Haubrich, R. H., Wang, C. Y., Chokkalingam, A. P., Osinusi, A. O., Wendtner, C. M., & Gottlieb, R. L. (2024). Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae336
Vancouver
Fusco D, Malenica I, Günthard HF, Gupta SK, Kurbegov D, Balani B, et al. Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae336
BibTeX
@article{Fusco2024,
author = {Fusco, Dahlene and Malenica, Ivana and Günthard, Huldrych F and Gupta, Samir K and Kurbegov, Dax and Balani, Bindu and Olender, Susan and Aberg, Judith A and Telep, Laura E and Tian, Yuan and Blair, Christiana and Wu, George and Haubrich, Richard H and Wang, Chen-Yu and Chokkalingam, Anand P and Osinusi, Anu O and Wendtner, Clemens-Martin and Gottlieb, Robert L},
title = {Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae336}
}
EUVIMED